Related Experiment Videos
[Circulating immune complex and complement (C3) in a course of pulmonary tuberculosis]
Anna Dubaniewicz1, Magdalena Sztaba-Kania
1Katedra i Zakład Fizjopatologii AM w Gdański. aduban@amedec.amg.gda.pl
Summary
Circulating immune complexes (CIC) involving Erythrocyte-Antibody (EA) and Erythrocyte-Antibody-Complement (EAC) are elevated in tuberculosis patients. These immune complexes and C3 levels vary with disease activity and treatment, suggesting their role in tuberculosis pathogenesis.
Area of Science:
- Immunology
- Infectious Diseases
- Biochemistry
Context:
- Tuberculosis (TB) remains a significant global health challenge.
- Immune system dysregulation is implicated in TB pathogenesis.
- Circulating immune complexes (CIC) are potential biomarkers in infectious diseases.
Purpose:
- To investigate plasma levels of Erythrocyte-Antibody (EA) and Erythrocyte-Antibody-Complement (EAC) CIC, and C3 complement component in healthy volunteers and patients with active and inactive pulmonary tuberculosis.
- To assess the changes in CIC and C3 levels before and after anti-tuberculous therapy.
Summary:
- The study found significantly higher levels of EA and EAC CIC in all TB patient groups compared to healthy controls.
- CIC levels showed variations between active and inactive TB, and C3 levels were elevated in active TB patients, decreasing after treatment.
- Different detection methods (RI EA and RI EAC tests) yielded varying results depending on TB activity.
Impact:
- The findings suggest that EA and EAC CIC and C3 component variability are associated with TB disease activity and treatment response.
- Elevated CIC levels may indicate an ongoing or partially resolved mycobacterial process, even in the inactive stage.
- These CIC could serve as potential diagnostic or prognostic markers in tuberculosis management.